Focus
Rexulti
LATEST
An Antipsychotic Drug Gets FDA Green Light Despite Fourfold Higher Risk of Death
For medical professionals, the FDA’s move raises troubling questions about efficacy, safety, and regulatory diligence.
|
For medical professionals, the FDA’s move raises troubling questions about efficacy, safety, and regulatory diligence.